Role of the RAGE Axis during the Immune Response after Severe Trauma: A Prospective Pilot Study

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Uhle, Florian ^a   Lichtenstern, Christoph ^a   Brenner, Thorsten ^a   Fleming, Thomas ^a   Koch, Christian ^b   Hecker, Andreas ^b   Heiss, Christian ^c   Nawroth, Peter Paul ^a   Hofer, Stefan ^a   Weigand, Markus Alexander ^a   Weismüller, Katja ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCOSE; HLA DR ANTIGEN; INTERLEUKIN 6; METHYLGLYOXAL; AGER PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; LIGAND;

ABDOMINAL SURGERY; ADULT; ARTICLE; BLOOD SAMPLING; CELL SURFACE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; INJURY; INJURY SCALE; MALE; MONOCYTE; OBSERVATIONAL STUDY; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; AGED; BLOOD; CASE CONTROL STUDY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGICAL STRESS; VERY ELDERLY; YOUNG ADULT;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-6; LIGANDS; MALE; MIDDLE AGED; MONOCYTES; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRUVALDEHYDE; STRESS, PHYSIOLOGICAL; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84956898050     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/691491     Document Type: Article

References (38)

1. C. J. L. Murray and A. D. Lopez, "Alternative projections of mortality and disability by cause 1990-2020: global Burden of Disease study, " The Lancet, vol. 349, no. 9064, pp. 1498-1504, 1997.
2. E. G. Krug, G. K. Sharma, and R. Lozano, "The global burden of injuries, " American Journal of Public Health, vol. 90, no. 4, pp. 523-526, 2000.
3. H. E. Campbell, E. A. Stokes, D. N. Bargo et al., "Quantifying the healthcare costs of treating severely bleeding major trauma patients: a national study for England, " Critical Care, vol. 19, article 276, 2015.
4. M. Keel and O. Trentz, "Pathophysiology of polytrauma, " Injury, vol. 36, no. 6, pp. 691-709, 2005.
5. M. Levi and T. van der Poll, "Inflammation and coagulation, " Critical Care Medicine, vol. 38, no. 2, supplement, pp. S26-S34, 2010.
6. M. E. Bianchi, "DAMPs, PAMPs and alarmins: all we need to know about danger, " Journal of Leukocyte Biology, vol. 81, no. 1, pp. 1-5, 2007.
7. T. Kislinger, C. Fu, B. Huber et al., " -(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression, "The Journal of Biological Chemistry, vol. 274, no. 44, pp. 31740-31749, 1999.
8. J. Xue, V. Rai, D. Singer et al., "Advanced glycation end product recognition by the receptor for AGEs, " Structure, vol. 19, no. 5, pp. 722-732, 2011.
9. Y. K. Chuah, R. Basir, H. Talib, T. H. Tie, and N. Nordin, "Receptor for advanced glycation end products and its involvement in inflammatory diseases, " International Journal of Inflammation, vol. 2013, Article ID403460, 15 pages, 2013.
10. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury, " Circulation, vol. 114, no. 6, pp. 597-605, 2006.
11. V. P. Singh, A. Bali, N. Singh, and A. S. Jaggi, "Advanced glycation end products and diabetic complications, " Korean Journal of Physiology and Pharmacology, vol. 18, no. 1, pp. 1-14, 2014.
12. S. F. Yan, R. Ramasamy, and A. M. Schmidt, "Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging, " Biochemical Pharmacology, vol. 79, no. 10, pp. 1379-1386, 2010.
13. C. Bopp, S. Hofer, J. Weitz et al., "sRAGE is elevated in septic patients and associated with patients outcome, " Journal of Surgical Research, vol. 147, no. 1, pp. 79-83, 2008.
14. H. Matsumoto, N. Matsumoto, H. Ogura et al., "The clinical significance of circulating soluble RAGE in patients with severe sepsis, " Journal of Trauma and Acute Care Surgery, vol. 78, no. 6, pp. 1086-1094, 2015.
15. F. Kimura, H. Shimizu, H. Yoshidome, M. Ohtsuka, and M. Miyazaki, "Immunosuppression following surgical and traumatic injury, " Surgery Today, vol. 40, no. 9, pp. 793-808, 2010.
16. F. Uhle, D. van denNouland, S. Little et al., "Plasmatic isoforms of cytokeratin 18 and RAGE after severe trauma: a longitudinal cohort study, " Journal of Trauma and Acute Care Surgery, vol. 77, no. 4, pp. 577-584, 2014.
17. M. J. Cohen, M. Carles, K. Brohi et al., "Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans, " Journal of Trauma-Injury, Infection & Critical Care, vol. 68, no. 6, pp. 1273-1278, 2010.
18. P. J. Thornalley, A. Langborg, and H. S. Minhas, "Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose, " The Biochemical Journal, vol. 344, part 1, pp. 109-116, 1999.
19. A. C. McLellan, S. A. Phillips, and P. J. Thornalley, "The assay of methylglyoxal in biological systems byderivatization with 1, 2-diamino-4, 5-dimethoxybenzene, " Analytical Biochemistry, vol. 206, no. 1, pp. 17-23, 1992.
20. L. Zeng, "Rs1800625 in the receptor for advanced glycation end products gene predisposes to sepsis and multiple organ dysfunction syndrome in patients with major trauma, " Critical Care, vol. 19, article 1, 7 pages, 2015.
21. S. T. Buckley and C. Ehrhardt, "The receptor for advanced glycation end products (RAGE) and the lung, " Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 917108, 11 pages, 2010.
22. D. J. Weber, A. S. A. Gracon, M. S. Ripsch et al., "The HMGB1-RAGE axis mediates traumatic brain injury-induced pulmonary dysfunction in lung transplantation, " Science Translational Medicine, vol. 6, no. 252, Article ID 252ra124, 2014.
23. C. Martin, C. Boisson, M. Haccoun, L. Thomachot, and J.-L. Mege, "Patterns of cytokine evolution (tumor necrosis factor-α and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma, " Critical Care Medicine, vol. 25, no. 11, pp. 1813-1819, 1997.
24. M. J. Cohen, K. Brohi, C. S. Calfee et al., "Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion, " Critical Care, vol. 13, article R174, 2009.
25. R. K. Aneja, A. Tsung, H. Sjodin et al., "Preconditioning with highmobility group box 1(HMGB1) induces lipopolysaccharide (LPS) tolerance, " Journal of Leukocyte Biology, vol. 84, no. 5, pp. 1326-1334, 2008.
26. A. Liesz, A. Dalpke, E. Mracsko et al., "DAMP signaling is a key pathway inducing immune modulation after brain injury, " The Journal of Neuroscience, vol. 35, no. 2, pp. 583-598, 2015.
27. Q. Zhang, M. Raoof, Y. Chen et al., "Circulating mitochondrial DAMPs cause inflammatory responses to injury, " Nature, vol. 464, no. 7285, pp. 104-107, 2010.
28. A. Raucci, S. Cugusi, A. Antonelli et al., "A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10), " The FASEB Journal, vol. 22, no. 10, pp. 3716-3727, 2008.
29. F. Venet, S. Tissot, A.-L. Debard et al., "Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock, " Critical Care Medicine, vol. 35, no. 8, pp. 1910-1917, 2007.
30. D. Foell, H. Wittkowski, C. Kessel et al., "Proinflammatory S100A12 can activate humanmonocytes via toll-like receptor 4, " American Journal of Respiratory and Critical CareMedicine, vol. 187, no. 12, pp. 1324-1334, 2013.
31. J. Austermann, J. Friesenhagen, S. Fassl et al., "Alarmins MRP8 and MRP14 induce stress tolerance in phagocytes under sterile inflammatory conditions, " Cell Reports, vol. 9, no. 6, pp. 2112-2124, 2014.
32. E. Ĺopez-Collazo and C. del Fresno, "Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences, " Critical Care, vol. 17, no. 6, article 242, 2013.
33. S. E. Shoelson, J. Lee, and A. B. Goldfine, "Inflammation and insulin resistance, "The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793-1801, 2006.
34. N. Ahmed, R. Babaei-Jadidi, S. K. Howell, P. J. Beisswenger, and P. J. Thornalley, "Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes, " Diabetologia, vol. 48, no. 8, pp. 1590-1603, 2005.
35. T. Brenner, T. Fleming, F. Uhle et al., "Methylglyoxal as a new biomarker in patients with septic shock: an observational clinical study, " Critical Care, vol. 18, article 683, 2014.
36. A. Bierhaus, T. Fleming, S. Stoyanov et al., "Methylglyoxal modification ofNa v 1. 8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy, " Nature Medicine, vol. 18, no. 6, pp. 926-933, 2012.
37. I. M. Chiu, B. A. Heesters, N. Ghasemlou et al., "Bacteria activate sensory neurons that modulate pain and inflammation, " Nature, vol. 501, no. 7465, pp. 52-57, 2013.
38. R. Deane, I. Singh, A. P. Sagare et al., "A multimodal RAGEspecific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease, " The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1377-1392, 2012.